The CMO industry is undergoing a wave of ownership changes, including acquisitions, divestitures, and initial public offerings (IPOs). Ownership changes can lead to significant changes in a company’s strategy, focus, and prospects, so it is important for bio/pharmaceutical companies to review the implications of a key supplier’s change in ownership, writes Jim Miller.
Recently announced ownership changes read like a veritable “Who’s Who” of the CMO industry:
• Catalent Pharma Solutions (Somerset, NJ, USA) will become a publicly traded company after completing an IPO later this year. Catalent has been owned by a group of private equity firms, led by Blackstone Group.
• Recipharm (Stockholm, Sweden) will also float an IPO, according to European press reports.
• Patheon (RTP, NC, USA) and DSM Pharmaceutical Products (DPP?Parsippany, NJ, USA) will be merged into an as-yet unnamed new private company owned by private equity firm JLL Partners and DSM N.V. Patheon has been a public company while DPP has been a strategic business unit of publicly-traded DSM N.V.
• JHP Pharmaceuticals (Parsippany, NJ, USA) is being acquired by Par Pharmaceuticals.
• Cangene bioPharma (Baltimore, MD, USA) is being acquired along with its parent Cangene Corporation by Emergent BioSolutions.
• Haupt Pharma (Berlin, Germany) has been acquired by private equity-backed CMO Aenova Group (Pahl, Germany). Haupt was previously owned by a private equity firm.
For the rest of Jim Miller’s article, click here.